Castrate Resistent Prostate Cancer
1 clinical trials · Condition
◉ Watch Castrate Resistent Prostate Cancer
| Record | Firm | Date |
|---|---|---|
| Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer (NCT01823978) | Bellicum Pharmaceuticals | 2013-04-01 |
Track Castrate Resistent Prostate Cancer automatically
Every clearance here is in the API, with alerts when new ones post.